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Of fifteen HIV-infected persons who 
underwent hematopoietic cell 
transplantation (HCT) on combination 
antiretroviral therapy, ten had 
sustained virologic suppression, while 
five had low-level HIV RNA, which 
was quickly suppressed upon therapy 
modification. Each color represents a 
different patient. The dotted line 
represents the limit of detection. 
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Johnston. 
 
 
Antiretroviral therapy (ART) has deeply transformed the outcome and management of HIV infection. 
Thanks to its ability to control viral replication and CD4+ T cell depletion, ART introduction has 
changed the HIV epidemic from a fatal disease to a chronic infection. As such, other health 
conditions can emerge as a result of longer survival and aging, as an effect of either HIV infection or 
prolonged therapy. Blood malignancies, such as non-Hodgkin lymphomas, leukemias and myelomas 
disproportionally affect HIV-infected subjects. While at the beginning of the HIV epidemic bone 
marrow transplantation (BMT) was not appropriate for HIV-infected subjects for the possible 
recrudescence of viral replication, the advent of ART changed the scenario. In fact, outcomes of 
autologous and, to a certain extent, of allogenic bone marrow transplantations have a similar 
success rate in HIV infected and uninfected subjects. Furthermore, the only documented HIV cure 
occurred in a subject that received bone marrow from an HIV-resistant donor, carrying the mutation 
that causes a lack of expression of CCR5, co-receptor for HIV infection. Although the situation was 
pretty unique, the transplantation was successful, the patient has still undetectable viral load and is 
cancer-free (See the featured story of the Berlin patient). 
The conundrum now to be faced is whether the ART regimen should be maintained during the 
transplantation. In fact, while maintaining the anti-retroviral regimen could be beneficial by inhibiting 
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viral expansion and infection of the transplanted cells, it could also create interactions with 
chemotherapy or immunosuppressive drugs. Drs. Christine Johnston (Vaccine and Infectious 
Disease Division) and Ann Woolfrey (Clinical Research Division) from the Fred Hutch, together with 
a group of scientists affiliated with Fred Hutch and University of Washington, addressed this 
question by looking at the outcomes of 15 bone marrow transplantats carried on HIV-positive 
subjects receiving ART. The study was recently published in the journal Biology of Blood and 
Marrow Transplantation. 
The observation of the outcomes was informative on different aspects of the BMT procedure. First of 
all, ART was well tolerated in all patients: in eight cases, ART was uninterrupted for the duration of 
the procedure, while few doses were missed by the remaining patients due to side effects of the 
drugs. ART regimens maintained the viral RNA plasma load below the detection limit in all but five 
patients, some of whom required a modification in the treatment, which promptly decreased the viral 
load to undetectable levels for an average time of 259 days. Importantly, the treatment did not 
modify the transplantation course, and no adverse interactions between ART and either 
chemotherapy or immunosuppressive drugs were observed. Four patients were cancer-free at the 
end of the study, while malignant disease relapse was observed in eleven other patients. 
Even though the study describes the effects of maintaining ART during bone marrow transplantation 
only in 15 participants, the results strongly support its use, so much that the authors have now 
outlined recommendation for ART use in HIV-infected individuals undergoing transplantation. This 
study shed light on a central question and will be of fundamental importance for the clinical 
management of HIV-infected subjects affected by blood malignancies. Dr. Johnston said: "This work 
demonstrates that combination ART, which is selected to minimize drug-drug interactions and 
maximize tolerability can be safely given to persons with HIV infection during hematopoietic cell 
transplant (HCT).  ART maintains HIV suppression without introduction of resistance during the peri-
transplant period.  These data have implications not only for HIV-infected persons undergoing HCT 
for hematologic malignancies, but may also be relevant for strategies which are being investigated to 
"cure" HIV." 
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